MPO and vasculitis: Alternative dosing strategies with longer dosing intervals and dosing according to peripheral blood CD19 B cell return and PR3/MPO-ANCA rise may be reasonable, temporarily, in stable vasculitis patients with low relapse risk and experienced clinician oversight, to help optimise vaccine responses [19].